Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

0(0%)

Results Posted

100%(1 trials)

Phase Distribution

Ph phase_2

33%

Ph phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 1Safety & dosage

1(50.0%)

Phase 2Efficacy & side effects

1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(1)

Other(1)

Detailed Status

Completed1

unknown1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (50.0%)

Phase 21 (50.0%)

Trials by Status

completed133%

unknown133%

withdrawn133%

Recent Activity

0 active trials

Showing 3 of 3

unknown

Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib

NCT04757259

withdrawnphase_2

CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

NCT04021082

completedphase_1

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

NCT01994382

Clinical Trials (3)

Showing 3 of 3 trials

NCT04757259

Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib

Unknown

NCT04021082Phase 2

CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

Withdrawn

NCT01994382Phase 1

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3